King Pharma to lay off 20 percent

It's not just Big Pharma that's restructuring. King Pharmaceuticals plans to lay off 20 percent of its workforce and embark on a cost-cutting regime. The prompt: Possible loss of patent coverage on its Altace remedy for heart failure and high blood pressure. A U.S. Court of Appeals recently ruled against the company, but King has asked the judges to reconsider.

- check out King's release

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.